Literature DB >> 14991075

Increased CD36 protein as a response to defective insulin signaling in macrophages.

Chien-Ping Liang1, Seongah Han, Haruka Okamoto, Ronald Carnemolla, Ira Tabas, Domenico Accili, Alan R Tall.   

Abstract

Accelerated atherosclerosis is a major cause of morbidity and death in insulin-resistant states such as obesity and the metabolic syndrome, but the underlying mechanisms are poorly understood. We show that macrophages from obese (ob/ob) mice have increased binding and uptake of oxidized LDL, in part due to a post-transcriptional increase in CD36 protein. Macrophages from ob/ob mice are also insulin resistant, as shown by reduced expression and signaling of insulin receptors. Three lines of evidence indicate that the increase in CD36 is caused by defective insulin signaling: (a) Treatment of wild-type macrophages with LY294002, an inhibitor of insulin signaling via PI3K, results in an increase in CD36; (b) insulin receptor knockout macrophages show a post-transcriptional increase in CD36 protein; and (c) administration of thiazolidinediones to intact ob/ob mice and ob/ob, LDL receptor-deficient mice results in a reversal of macrophage insulin receptor defects and decreases CD36 protein. The last finding contrasts with the increase in CD36 that results from treatment of macrophages with these drugs ex vivo. The results suggest that defective macrophage insulin signaling predisposes to foam cell formation and atherosclerosis in insulin-resistant states and that this is reversed in vivo by treatment with PPAR-gamma activators.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991075      PMCID: PMC351316          DOI: 10.1172/JCI19528

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  53 in total

1.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.

Authors:  A H Berg; T P Combs; X Du; M Brownlee; P E Scherer
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

2.  A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation.

Authors:  E Griffin; A Re; N Hamel; C Fu; H Bush; T McCaffrey; A S Asch
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

Review 3.  Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia.

Authors:  Gerald M Reaven
Journal:  Diabetes Obes Metab       Date:  2002-01       Impact factor: 6.577

4.  Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.

Authors:  A R Collins; W P Meehan; U Kintscher; S Jackson; S Wakino; G Noh; W Palinski; W A Hsueh; R E Law
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

5.  Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

Authors:  Z Chen; S Ishibashi; S Perrey; T Gotoda; T Kitamine; Y Tamura; H Okazaki; N Yahagi; Y Iizuka; F Shionoiri; K Ohashi; K Harada; H Shimano; R Nagai; N Yamada
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

6.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice.

Authors:  M Febbraio; E A Podrez; J D Smith; D P Hajjar; S L Hazen; H F Hoff; K Sharma; R L Silverstein
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

7.  Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

Authors:  T Claudel; M D Leibowitz; C Fiévet; A Tailleux; B Wagner; J J Repa; G Torpier; J M Lobaccaro; J R Paterniti; D J Mangelsdorf; R A Heyman; J Auwerx
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

8.  Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells.

Authors:  V C Hannah; J Ou; A Luong; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

9.  Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.

Authors:  H Koshiyama; D Shimono; N Kuwamura; J Minamikawa; Y Nakamura
Journal:  J Clin Endocrinol Metab       Date:  2001-07       Impact factor: 5.958

10.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.

Authors:  J Fruebis; T S Tsao; S Javorschi; D Ebbets-Reed; M R Erickson; F T Yen; B E Bihain; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  73 in total

1.  You are right too!

Authors:  Joseph L Witztum
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 2.  Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes.

Authors:  Robert D Stout; Jill Suttles
Journal:  Immunol Rev       Date:  2005-06       Impact factor: 12.988

3.  Surface protein expression between human adipose tissue-derived stromal cells and mature adipocytes.

Authors:  Franck Festy; Laurence Hoareau; Sandrine Bes-Houtmann; Anne-Marie Péquin; Marie-Paule Gonthier; Ashik Munstun; Jean Jacques Hoarau; Maya Césari; Régis Roche
Journal:  Histochem Cell Biol       Date:  2005-09-29       Impact factor: 4.304

4.  Molecular basis of human CD36 gene mutations.

Authors:  Monika Ewa Rać; Krzysztof Safranow; Wojciech Poncyljusz
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

5.  OxLDL or TLR2-induced cytokine response is enhanced by oxLDL-independent novel domain on mouse CD36.

Authors:  Chenghui Xie; Hangpong Ng; Shanmugam Nagarajan
Journal:  Immunol Lett       Date:  2011-01-31       Impact factor: 3.685

6.  Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages.

Authors:  Bardia Askari; Jenny E Kanter; Ashley M Sherrid; Deidre L Golej; Andrew T Bender; Joey Liu; Willa A Hsueh; Joseph A Beavo; Rosalind A Coleman; Karin E Bornfeldt
Journal:  Diabetes       Date:  2007-01-26       Impact factor: 9.461

7.  Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis.

Authors:  Julia Baumgartl; Stephanie Baudler; Maximilian Scherner; Vladimir Babaev; Liza Makowski; Jill Suttles; Marcia McDuffie; Kazuyuki Tobe; Takashi Kadowaki; Sergio Fazio; C Ronald Kahn; Gökhan S Hotamisligil; Wilhelm Krone; Macrae Linton; Jens C Brüning
Journal:  Cell Metab       Date:  2006-04       Impact factor: 27.287

Review 8.  Macrophage death and defective inflammation resolution in atherosclerosis.

Authors:  Ira Tabas
Journal:  Nat Rev Immunol       Date:  2009-12-04       Impact factor: 53.106

Review 9.  The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression.

Authors:  Ira Tabas; Alan Tall; Domenico Accili
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

10.  Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages.

Authors:  Yinan Hua; Machender R Kandadi; Meijun Zhu; Jun Ren; Nair Sreejayan
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.